Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, ...
Fast track status supports expedited development/review for a serious hematologic malignancy with limited second-line therapy after HMA failure. CyTAC engineering merges small-molecule CCR2 binding ...
CASTRES, France & BOSTON--(BUSINESS WIRE)--Pierre Fabre Laboratories, a global player in oncology, and Scorpion Therapeutics, Inc. (“Scorpion”), a pioneering clinical-stage oncology company dedicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results